Toth Financial Advisory’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Toth Financial Advisory’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11	Closed	-$56	–	802
2024 Q1	$56	Buy	+11	New	+$68	﹤0.01%	714
2023 Q4	–	Sell	-11	Closed	-$103	–	809
2023 Q3	$103	Hold	11	–	–	﹤0.01%	746
2023 Q2	$236	Hold	11	–	–	﹤0.01%	756
2023 Q1	$301	Buy	+11	New	+$512	﹤0.01%	789

Other funds holding EIGR

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Toth Financial Advisory's EIGR Position: Q2 2024 in Review

Toth Financial Advisory sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 11 shares — an estimated $56 sold.

Toth Financial Advisory first reported a position in EIGR in Q1 2023 and held it in 4 quarters. The position peaked at $301 in Q1 2023. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

Toth Financial Advisory reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Toth Financial Advisory sold 11 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $56.
Toth Financial Advisory first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2023 and held it in 4 quarters.
Toth Financial Advisory's Eiger BioPharmaceuticals, Inc. position peaked at $301 in Q1 2023.
2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Toth Financial Advisory's 13F filing for Q2 2024, filed 16 Jul 2024.